Sign Up Today and Learn More About Pathos Stock
Invest in or calculate the value of your shares in Pathos or other pre-IPO companies through EquityZen's platform.
Pathos Stock (PAT)
Pathos develops an AI-enabled drug discovery platform to reduce the medication development process.
About Pathos Stock
Founded
2020
Headquarters
Chicago, IL, US
Industries
Software, Artificial Intelligence, Data and Analytics
Pathos Press Mentions
Stay in the know about the latest news on Pathos
The Week’s Biggest Funding Rounds: Pathos, Addepar Top Busy Week For Health And Fintech
news • May 16, 2025
Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development
globenewswire • May 08, 2025
Tempus AI Stock: Time to Double Down or Cut and Run?
marketbeat • May 08, 2025
Tempus Reports First Quarter 2025 Results
morningstar • May 06, 2025
32 startups left in Inno Madness 2025
bizjournals • Mar 26, 2025
Pathos Management
Leadership team at Pathos
CEO and Cofounder
Ryan Fukushima
Chief Operating Officer
Matt De Silva
Join now and verify your accreditation status to gain access to:
- Pathos Current Valuation
- Pathos Stock Price
- Pathos Management
- Available deals in Pathos and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Pathos Cap Table and Funding History by Share Class and Liquidity Preferences
- Pathos Revenue and Financials
- Pathos Highlights
- Pathos Business Model
- Pathos Risk Factors
- Pathos Research Report from SACRA Research
Trading Pathos Stock
How to invest in Pathos stock?
Accredited investors can buy pre-IPO stock in companies like Pathos through EquityZen funds. These investments are made available by existing Pathos shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Pathos stock?
Shareholders can sell their Pathos stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
